Tetraphase Pharmaceuticals, Inc. (TTPH) Earns “Hold” Rating from Needham & Company LLC
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)‘s stock had its “hold” rating reaffirmed by analysts at Needham & Company LLC in a report released on Thursday.
Several other analysts have also commented on TTPH. BMO Capital Markets reissued an “outperform” rating and set a $13.00 price target (up from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $8.00 to $15.00 in a research report on Wednesday. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 price target for the company. Finally, Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $10.25.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 11.68% on Thursday, reaching $6.96. 3,874,885 shares of the company were exchanged. The company’s market capitalization is $264.17 million. The company’s 50-day moving average is $7.48 and its 200-day moving average is $6.84. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.46 million. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The business’s quarterly revenue was down 24.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.46) earnings per share. On average, equities analysts expect that Tetraphase Pharmaceuticals will post ($2.66) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Earns “Hold” Rating from Needham & Company LLC” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/27/tetraphase-pharmaceuticals-inc-ttph-earns-hold-rating-from-needham-company-llc.html.
A number of institutional investors have recently modified their holdings of TTPH. Vanguard Group Inc. increased its position in shares of Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares during the period. Tekla Capital Management LLC increased its position in shares of Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock valued at $9,230,000 after buying an additional 812,000 shares during the period. State Street Corp boosted its stake in shares of Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock worth $2,864,000 after buying an additional 11,391 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 408,078 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock worth $3,482,000 after buying an additional 197,022 shares during the last quarter. Institutional investors own 46.24% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.